当前位置: 首页 >> 检索结果
61. Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
作者: Narumi Harada-Shoji.;Akihiko Suzuki.;Takanori Ishida.;Seiichiro Yamamoto.;Seiki Kanemura.;Takuhiro Yamaguchi.;Yoko Shiono-Narikawa.;Noriaki Ohuchi.; .
来源: Lancet. 2026年407卷10530期784-793页
The J-START randomised controlled trial found that adjunctive ultrasonography was associated with significantly higher rates of breast cancer detection than mammography alone. This report aims to evaluate the long-term effect of adjunctive ultrasonography screening on the cumulative incidence of advanced breast cancer as a prespecified secondary outcome of J-START.
62. Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.
作者: Yunyun Xiong.;Fana Alemseged.;Zhixin Cao.;Lee H Schwamm.;Si Zhang.;Mark W Parsons.;Marc Fisher.;Yahui Hao.;Aoming Jin.;Jinfeng Yin.;Yong Jiang.;Fengyuan Che.;Lihua Wang.;Li Zhou.;Hongguo Dai.;Yutie Zhao.;Chunmiao Duan.;Shuangzhe Wu.;Ganghua Feng.;Lixia Zong.;Wanxing Ye.;Ziran Wang.;Ziqi Xu.;Hao Wang.;Manjun Hao.;Yujie Ma.;Xia Meng.;Hao Li.;Zixiao Li.;Yilong Wang.;Liping Liu.;Xingquan Zhao.;Bruce C V Campbell.;Yongjun Wang.; .
来源: Lancet. 2026年407卷10530期763-772页
The efficacy and safety of intravenous thrombolysis with tenecteplase within 24 h after stroke onset due to basilar artery occlusion are not well studied. We aimed to assess whether intravenous tenecteplase administered within 24 h after symptom onset improved functional outcome compared with standard medical treatment in patients with basilar artery occlusion.
63. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Mazen Noureddin.;Kris V Kowdley.;Tatjana Odrljin.;Gerard Bain.;Jeff Zhao.;Brenda Jeglinski.;Margaret James Koziel.;Rohit Loomba.
来源: Lancet. 2026年407卷10530期794-804页
The growing prevalence of metabolic dysfunction-associated steatohepatitis (MASH) underscores the unmet need for effective and safe liver-targeted therapies to prevent fibrosis and disease progression. The aim of this study was to evaluate the efficacy and safety of efimosfermin alfa (henceforth referred to as efimosfermin, formerly BOS-580), an FGF21 analogue taken once per month, in patients with MASH and moderate or advanced fibrosis.
64. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
作者: Amy E Colson.;Anthony M Mills.;Moti N Ramgopal.;Christopher Bettacchi.;Olayemi O Osiyemi.;Federico Hinestrosa.;Gordon Crofoot.;Harold P Katner.;Hiroyuki Gatanaga.;Margaret Johnson.;Tracy L Diamond.;Erika Barninger.;Karen Eves.;Feng-Hsiu Su.;Yayun Xu.;Stephanie O Klopfer.;Luisa M Stamm.;Michelle C Fox.;Rima Lahoulou.
来源: Lancet. 2026年407卷10528期611-621页
The combination of doravirine and islatravir is under investigation as a fixed-dose, single-tablet regimen for the treatment of HIV-1. We aimed to assess the efficacy and safety of switching to doravirine (100 mg) and islatravir (0·25 mg) from bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV-1.
65. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
作者: Chloe Orkin.;Rosie Mngqibisa.;Juan Diego Velez.;Princy Kumar.;Dominique L Braun.;Andrew Carr.;Mark Bloch.;Sharon Walmsley.;Pablo Tebas.;Yoshiyuki Yokomaku.;Tracy L Diamond.;Beth Jackson.;Karen Eves.;Anjana Grandhi.;Monica Fuszard.;Stephanie O Klopfer.;Luisa M Stamm.;Michelle C Fox.;Jason Kim.
来源: Lancet. 2026年407卷10528期599-610页
Doravirine and islatravir is an investigational, once-daily, single-tablet regimen containing two potent antiretrovirals with complementary mechanisms of action and resistance profiles. We aimed to evaluate the efficacy and safety of switching from stable, oral antiretroviral therapy (ART) to the fixed combination of doravirine (100 mg) and islatravir (0·25 mg) in virologically suppressed adults living with HIV-1.
66. Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
作者: Joseph P Broderick.;Andrew M Naidech.;Jordan J Elm.;Kazunori Toyoda.;Dar Dowlatshahi.;Andrew M Demchuk.;Pooja Khatri.;Thorsten Steiner.;Philip M Bath.;Heinrich J Audebert.;Achala Vagal.;Sohei Yoshimura.;Stephan A Mayer.;Lily L Wang.;Noor Sabagha.;J D Mocco.;Carlos Molina.;Richard Aviv.;Emily Stinson.;Syed A Quadri.;Janice Carrozzella.;Thien Huynh.;Anh Phan.;Jonathan Beall.;Iris Davis.;Nobuyuki Sakai.;Tsuyoshi Ohta.;Michiko Yokosawa.;Takayuki Hara.;Navdeep Sangha.;Kenichi Morita.;Ming Yin Dominc Tse.;Christopher D Streib.;Fumio Miyashita.;Yolanda Silva.;Yoshinari Nagakane.;Tudor Gheorghiu.;Chung-Huan Sun.;Teruyuki Hirano.;Sven Poli.;Tsuyoshi Izumo.;Mayumi Fukuda-Doi.;Masafumi Ihara.;Masatoshi Koga.;Brian Buck.;Kyle B Walsh.;Ilana Spokovny.;James C Grotta.; .
来源: Lancet. 2026年407卷10530期773-783页
Recombinant factor VIIa has been shown to slow bleeding in patients with intracerebral haemorrhage (ICH), but no haemostatic agent has been shown to improve clinical outcomes. We aimed to evaluate the safety, clinical efficacy, and effect on growth of ICH and intraventricular haemorrhage (IVH) of recombinant factor VIIa in patients with acute spontaneous ICH who were most likely to benefit from treatment with this agent.
67. Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
作者: Jeehoon Kang.;Kyung Woo Park.;Jung-Kyu Han.;Doyeon Hwang.;Han-Mo Yang.;Sungjoon Park.;Hyo-Suk Ahn.;Kyung-Kuk Hwang.;Byung Gyu Kim.;Jin-Ok Jeong.;Jong-Hwa Ahn.;Jay Young Rhew.;Hanbit Park.;Tae Soo Kang.;Jin-Sin Koh.;Kyung-Taek Park.;Duk Won Bang.;Choong-Won Goh.;Hyuck-Jun Yoon.;Sang-Ho Jo.;Ji Yong Jang.;Young Jin Choi.;Sang Rok Lee.;Young-Hyo Lim.;Hyo-Soo Kim.; .
来源: Lancet. 2025年406卷10516期2244-2256页
The optimal duration of dual antiplatelet therapy (DAPT) after coronary stenting according to bleeding risk is not well established. We aimed to evaluate the optimal duration of DAPT after coronary stenting according to bleeding risk.
68. Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
作者: Yao Lu.;Ling Guan.;Jialing Wu.;Qianqian Yang.;Meiyang Zhang.;Dongyang Zhou.;Hongqin Yang.;Yuesong Pan.;Luyan Wang.;Baoshan Qiu.;Chenhui Liu.;Yicong Wang.;Yingying Yang.;Xuejiao Zhou.;Hui Qu.;Xiaoling Liao.;Liping Liu.;Xingquan Zhao.;Philip M Bath.;S Claiborne Johnston.;Pierre Amarenco.;Guillaume Turc.;Fu-Dong Shi.;Yongjun Wang.;Yilong Wang.; .
来源: Lancet. 2026年407卷10529期679-688页
Minocycline has been reported as a multi-target anti-neuroinflammatory drug with potential benefits for ischaemic stroke in preclinical models and small-scale clinical studies. The EMPHASIS trial was designed to provide robust evidence regarding its efficacy and safety in patients with acute ischaemic stroke.
69. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial.
作者: Jessie Gommers.;Veronica Hernström.;Viktoria Josefsson.;Hanna Sartor.;David Schmidt.;Annie Hjelmgren.;Anna-Maria Larsson.;Solveig Hofvind.;Ingvar Andersson.;Aldana Rosso.;Oskar Hagberg.;Kristina Lång.
来源: Lancet. 2026年407卷10527期505-514页
Evidence indicates that artificial intelligence (AI) can improve mammography screening by increasing cancer detection and reducing screen reading workload, but its effect on interval cancers (primary breast cancers diagnosed between two screening rounds or within 2 years after the last scheduled screening that were not detected at screening) is unknown. We aimed to compare the interval cancer rate in AI-supported mammography screening with standard double reading without AI.
70. Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
作者: Mihir A Kelshiker.;Patrik Bächtiger.;Camille F Petri.;Saloni Nakhare.;Josephine Mansell.;Karanjot Chhatwal.;Abdullah Alrumayh.;Jahed Zaman.;Moulesh Shah.;Holly Young.;Helena Roy.;Melanie T Almonte.;Céire Costelloe.;Yasmin Razak.;Azeem Majeed.;James P Howard.;Carys Barton.;Daniel B Kramer.;Carla M Plymen.;Nicholas S Peters.
来源: Lancet. 2026年407卷10529期704-715页
Early detection of cardiovascular disease is a global public health priority. Artificial intelligence (AI)-enabled stethoscopes offer robust performance characteristics in point-of-care detection of heart failure, atrial fibrillation, and valvular heart disease (VHD). We conducted a pragmatic, cluster-randomised controlled implementation trial to determine the real-world effect and implementation challenges of AI-stethoscopes.
71. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.
作者: Howard Trachtman.;Matthias Kretzler.;Loreto Gesualdo.;Nicholas Cross.;Biruh Workeneh.;Jessica Kaufeld.;Björn Meijers.;Zhiming Ye.;Qinkai Chen.;Vimal K Derebail.;Monica Suet Ying Ng.;Bo Ji.;Maximilian T Lobmeyer.;Silke Retlich.;Fabia T Licarião Rocha.;Srinivasa Prasad.;Nima Soleymanlou.
来源: Lancet. 2026年407卷10528期587-598页
In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.
72. Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation.
作者: Daniel C Perry.;Juul Achten.;Alex Zimmermann.;Rebecca Kandiyali.;Duncan Appelbe.;James G Wright.;David Ferguson.;Kemble Wang.;Nichola Wilson.;Amy Moscrop.;James Mason.;Daphne Kounali.;Matthew L Costa.; .
来源: Lancet. 2026年407卷10528期577-586页
Displaced medial epicondyle fractures are among the most controversial injuries in children, with increasing trends towards surgical fixation despite little supporting evidence. Approximately half of affected children undergo surgical fixation, while others receive non-surgical care. The SCIENCE trial aimed to determine whether surgical fixation to restore the position of the bone provides superior functional outcomes and is cost-effective compared with non-surgical care.
73. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
作者: Shun Lu.;Jie Wang.;Nong Yang.;Dongqing Lv.;Lijuan Chen.;Lin Wu.;Xingya Li.;Longhua Sun.;Yongfeng Yu.;Bo Jin.;Lin Yang.;Yubiao Guo.;Haipeng Xu.;Tienan Yi.;Aiping Zeng.;Xiaorong Dong.;Jianhua Chen.;Ziping Wang.;Hongrui Niu.;Ying Cheng.;Pinhua Pan.;Pengbo Deng.;Hongming Pan.;Xuhong Min.;Jun Bai.;Laiyu Liu.;Tongmei Zhang.;Juan Li.;Songhua Fan.;Michael M Shi.;Tony Mok.;Weiguo Su.; .
来源: Lancet. 2026年407卷10526期375-387页
Savolitinib combined with osimertinib is a potential novel therapy for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) harbouring MET amplification after progression on EGFR tyrosine kinase inhibitor (TKI) therapy. We aimed to evaluate the efficacy and safety of savolitinib-osimertinib versus standard of care platinum-based doublet chemotherapy in this patient population.
74. Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
作者: Derick Kimathi.;Aitana Juan-Giner.;Ndeye S Bob.;Benedict Orindi.;Maria L Namulwana.;Antoine Diatta.;Stanley Cheruiyot.;Gamou Fall.;Moussa Dia.;Mainga M Hamaluba.;Dan Nyehangane.;Henry K Karanja.;John N Gitonga.;Daisy Mugo.;Donwilliams O Omuoyo.;Mwatasa Hussein.;Elizaphan Oloo.;Naomi Kamau.;Jackline Wafula.;Josephine Bendera.;Namanya Silvester.;James Mwavita.;Musiimenta Joshua.;Jane M Thuranira.;Collins Agababyona.;Caroline Ngetsa.;Nalusaji Aisha.;Felix Moki.;Titus Buluku.;Marianne Munene.;Juliet Mwanga-Amumpaire.;Julius Lutwama.;John Kayiwa.;Eunice Kamaara.;Alan D Barrett.;Pontiano Kaleebu.;Philip Bejon.;Amadou A Sall.;Rebecca F Grais.;George M Warimwe.
来源: Lancet. 2026年407卷10527期497-504页
WHO recommends fractional dose vaccination to address yellow fever vaccine shortages during outbreaks. In adults, a 500 IU dose has recently been shown to be non-inferior to the full standard dose, but the minimum effective dose for children is unknown.
75. Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
作者: Alexandre Abizaid.;Roxana Mehran.;Angelo Oliva.;Daniel Chamié.;Rodolfo Staico.;Fazila Malik.;Maarten Vink.;Arief Kurniadi.;Davide Cao.;Piera Capranzano.;Benjamin Faurie.;Philippe Garot.;David Hildick-Smith.;Alfonso Ielasi.;Nikolaus Löffelhardt.;Sasko Kedev.;Darren Mylotte.;Krzysztof Milewski.;Valeria Paradies.;Thomas Schmitz.;Koen Teeuwen.;Luca Testa.;Ralph Toelg.;François Vochelet.;Birgit Vogel.;Joanna Wykrzykowska.;Samantha Sartori.;Antonio Colombo.;Shigeru Saito.;Marie-Claude Morice.; .
来源: Lancet. 2026年407卷10525期227-236页
In patients with coronary artery disease, diabetes increases the risk of restenosis and adverse cardiovascular events after percutaneous coronary intervention (PCI). The Abluminus DES+ is a thin-strut cobalt-chromium sirolimus-eluting stent (SES) with abluminal and balloon-surface coating intended to enhance drug delivery to the vessel wall. We aimed to compare the efficacy and safety of the Abluminus DES+ SES versus the XIENCE durable-polymer everolimus-eluting stent (EES) in patients with diabetes undergoing PCI.
76. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
作者: Jean Bourhis.;Anne Aupérin.;Christian Borel.;Gautier Lefebvre.;Severine Racadot.;Lionnel Geoffrois.;Xu Shan Sun.;Esma Saada.;Beatriz Cirauqui.;Tomasz Rutkowski.;Stephanie Henry.;Anouchka Modesto.;Alison Johnson.;Sophie Chapet.;Benoit Calderon.;Christian Sire.;Olivier Malard.;Matthieu Bainaud.;Antonio Da Silva Motta.;Sebastien Thureau.;Yoann Pointreau.;Pierre Blanchard.;Guillaume Buiret.;Laurence Bozec.;Stephane Lopez.;Julie Vanbockstael.;Matthieu Bosset.;Charlotte Greilsamer.;Amaury Daste.;Antoine Bruna.;France N'Guyen.;Maria Plana.;Eluska Iruarrizaga.;Stephane Temam.;Caroline Even.;Elisabeth Perez Ruiz.;Mahasti Bert.;Eleni Karamouza.;Juliette Thariat.;Joanna Kazmierska.;Amanda Psyrri.;Ricard Mesia.;Yungan Tao.
来源: Lancet. 2026年407卷10526期363-374页
Postoperative cisplatin and radiotherapy is the standard of care for high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The NIVOPOST-OP trial aimed to assess the efficacy and safety of programmed death 1 blockade by nivolumab added to cisplatin and radiotherapy in this setting.
77. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
作者: Alison Luckey.;Manica Balasegaram.;Lindley A Barbee.;Teresa A Batteiger.;Helen Broadhurst.;Stephanie E Cohen.;Sinead Delany-Moretlwe.;Henry J C de Vries.;Jodie A Dionne.;Katherine Gill.;Chris Kenyon.;Rossaphorn Kittiyaowamarn.;Drew Lewis.;John P Mueller.;Vimla Naicker.;Seamus O'Brien.;John P O'Donnell.;Nittaya Phanuphak.;Elizabeth Spooner.;Subasree Srinivasan.;Stephanie N Taylor.;Magnus Unemo.;Zinhle Zwane.;Edward W Hook.; .
来源: Lancet. 2026年407卷10524期147-160页
Development of new treatments for gonorrhoea is a global public health priority. We aimed to evaluate the efficacy and safety of zoliflodacin versus ceftriaxone plus azithromycin in patients with uncomplicated urogenital gonorrhoea.
78. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
作者: Steven J Frank.;Paul M Busse.;J Jack Lee.;David I Rosenthal.;Mike Hernandez.;David M Swanson.;Adam S Garden.;G Brandon Gunn.;Samir H Patel.;James W Snider.;Daniel J Ma.;Jason K Molitoris.;Nancy Y Lee.;Upendra Parvathaneni.;Mark W McDonald.;Noah S Kalman.;Alexander Lin.;Nasiruddin Mohammed.;Christina Henson.;Christian Hyde.;Gopal K Bajaj.;Sanford R Katz.;Roi Dagan.;William H Morrison.;Jay P Reddy.;C David Fuller.;Shalin J Shah.;Jack Phan.;Gregory M Chronowski.;Lauren Mayo.;Erich M Sturgis.;Renata Ferrarotto.;Xiaorong R Zhu.;Xiaodong Zhang.;Li Wang.;Katherine A Hutcheson.;Adel K El-Naggar.;Amy C Moreno.;Anna Lee.;Michael T Spiotto.;Neil D Gross.;Stephen Y Lai.;Jay J Liao.;Jonathan Paly.;Zhongxing Liao.;Robert L Foote.; .
来源: Lancet. 2026年407卷10524期174-184页
Radiotherapy is an integral component of treatment for oropharyngeal cancer. Toxicity from the current state-of-the-art photon radiotherapy, intensity-modulated radiation therapy (IMRT), has prompted the search for alternative, less toxic therapies. One such alternative that might de-intensify treatment is proton therapy. In this trial, we aimed to directly compare IMRT with intensity-modulated proton therapy (IMPT), both concurrent with systemic therapy, hypothesising comparable disease control and survival and lower toxicity.
79. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
作者: Lorenzo Falchi.;Marcel Nijland.;Huiqiang Huang.;Kim M Linton.;John F Seymour.;Rong Tao.;Michal Kwiatek.;Abel Costa.;Theodoros P Vassilakopoulos.;Richard Greil.;Ana Jiménez-Ubieto.;Shane A Gangatharan.;Ohad Benjamini.;Catherine Thieblemont.;Alessandra Tucci.;Anna Elinder-Camburn.;Arpad Illes.;Jan Novak.;Miguel A Pavlovsky.;Andrew McDonald.;Dok Hyun Yoon.;Dai Maruyama.;Gauri Sunkersett.;Jian P Mei.;Nabanita Mukherjee.;Feng Zhu.;Abualbishr Alshreef.;Elena Favaro.;Franck Morschhauser.; .
来源: Lancet. 2026年407卷10524期161-173页
An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy.
80. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
作者: Laurie H Sehn.;Kai Hübel.;Stefano Luminari.;Christian W Scholz.;Antonio Salar.;Shankara Paneesha.;Björn Engelbrekt Wahlin.;Panayiotis Panayiotidis.;Hui-Peng Lee.;Ana Jiménez-Ubieto.;Juan-Manuel Sancho.;Tae Min Kim.;Eva Domingo Domenech.;Takahiro Kumode.;Christina Poh.;Catherine Thieblemont.;Dries Deeren.;Edwin de Wit.;Michael Arbushites.;Irene Vassallo.;Marek Trneny.; .
来源: Lancet. 2026年407卷10524期133-146页
Follicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. We aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide and rituximab in this setting.
|